星空体育官方入口网站网址大全-登录入口官网

#新适应症#

62篇内容 | 1619人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1416237, encodeId=bedc141623e5a, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=重磅！欧唐静®（恩格列净片）新适应症在华获批，用于治疗射血分数降低的成人心力衰竭, objectType=article, longId=729048, objectId=5b2ee29048b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b2ee29048b5, replyNumber=0, likeNumber=72, createdTime=2022-06-11, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b2ee29048b5, moduleTitle=重磅！欧唐静®（恩格列净片）新适应症在华获批，用于治疗射血分数降低的成人心力衰竭, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5b2ee29048b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416236, encodeId=05d714162364e, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=“双靶组合”新适应症在我国获批，「达拉非尼」联合「曲美替尼」为BRAF V600突变型非小细胞肺癌患者带来新选择, objectType=article, longId=301601, objectId=430a301601f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=430a301601f4, replyNumber=0, likeNumber=70, createdTime=2022-03-26, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=430a301601f4, moduleTitle=“双靶组合”新适应症在我国获批，「达拉非尼」联合「曲美替尼」为BRAF V600突变型非小细胞肺癌患者带来新选择, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=430a301601f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416234, encodeId=ec691416234ef, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=再获新适应症！新型三唑类抗真菌药物康新博在我国获批，用于治疗成人侵袭性曲霉病, objectType=article, longId=293458, objectId=f26a2934582a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f26a2934582a, replyNumber=0, likeNumber=74, createdTime=2022-01-07, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f26a2934582a, moduleTitle=再获新适应症！新型三唑类抗真菌药物康新博在我国获批，用于治疗成人侵袭性曲霉病, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f26a2934582a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416233, encodeId=d042141623387, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=今日探报 | 百济神州抗PD-1抗体新适应症有望近期获批；基于NGS的CaptHPV液体活检方法，可用于不同类型HPV肿瘤检测, objectType=article, longId=293200, objectId=ccdc2932002c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccdc2932002c, replyNumber=0, likeNumber=68, createdTime=2022-01-01, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccdc2932002c, moduleTitle=今日探报 | 百济神州抗PD-1抗体新适应症有望近期获批；基于NGS的CaptHPV液体活检方法，可用于不同类型HPV肿瘤检测, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ccdc2932002c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416232, encodeId=e574141623244, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=君实生物特瑞普利单抗联合化疗一线治疗非小细胞肺癌的新适应症上市申请获受理, objectType=article, longId=259943, objectId=cceb25994367, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cceb25994367, replyNumber=0, likeNumber=68, createdTime=2021-12-12, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cceb25994367, moduleTitle=君实生物特瑞普利单抗联合化疗一线治疗非小细胞肺癌的新适应症上市申请获受理, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cceb25994367)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416231, encodeId=5bde141623154, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=君实生物特瑞普利单抗联合化疗用于鼻咽癌一线治疗的新适应症在中国获批上市, objectType=article, longId=221354, objectId=a16422135482, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a16422135482, replyNumber=0, likeNumber=78, createdTime=2021-12-02, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a16422135482, moduleTitle=君实生物特瑞普利单抗联合化疗用于鼻咽癌一线治疗的新适应症在中国获批上市, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a16422135482)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416235, encodeId=a94c1416235f4, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=「依维莫司」新适应症获批，乳腺癌治疗迎来“内分泌+”新时代, objectType=article, longId=290364, objectId=55a82903641f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55a82903641f, replyNumber=0, likeNumber=51, createdTime=2021-11-10, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55a82903641f, moduleTitle=「依维莫司」新适应症获批，乳腺癌治疗迎来“内分泌+”新时代, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=55a82903641f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416230, encodeId=444d1416230ac, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=纳入优先审评！恒瑞医药创新药吡咯替尼新适应症——新辅助治疗, objectType=article, longId=217708, objectId=bfcd21e7083b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfcd21e7083b, replyNumber=0, likeNumber=58, createdTime=2021-09-28, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfcd21e7083b, moduleTitle=纳入优先审评！恒瑞医药创新药吡咯替尼新适应症——新辅助治疗, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bfcd21e7083b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416229, encodeId=2cfe1416229d7, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=罗氏重磅新药舒友立乐®在华斩获新适应症，助力更多A型血友病患者迈向“零出血”自由人生, objectType=article, longId=210711, objectId=8b33210e118c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b33210e118c, replyNumber=0, likeNumber=60, createdTime=2021-05-02, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b33210e118c, moduleTitle=罗氏重磅新药舒友立乐®在华斩获新适应症，助力更多A型血友病患者迈向“零出血”自由人生, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8b33210e118c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416227, encodeId=85c4141622e3e, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=葛兰素史克中枢神经系统治疗药物利必通获批双相情感障碍新适应症, objectType=article, longId=208131, objectId=91b320813104, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91b320813104, replyNumber=0, likeNumber=56, createdTime=2021-03-09, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91b320813104, moduleTitle=葛兰素史克中枢神经系统治疗药物利必通获批双相情感障碍新适应症, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=91b320813104)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416226, encodeId=64c2141622667, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=葛兰素史克中枢神经系统治疗药物利必通获批新适应症，为双相情感障碍患者带来一线用药新选择, objectType=article, longId=207762, objectId=4aba20e76244, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4aba20e76244, replyNumber=0, likeNumber=68, createdTime=2021-03-02, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4aba20e76244, moduleTitle=葛兰素史克中枢神经系统治疗药物利必通获批新适应症，为双相情感障碍患者带来一线用药新选择, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4aba20e76244)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416228, encodeId=4520141622851, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=礼来制药与信达生物共同宣布达伯舒®（信迪利单抗注射液）非鳞状非小细胞肺癌一线治疗新适应症正式上市, objectType=article, longId=207677, objectId=f31920e677cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f31920e677cb, replyNumber=0, likeNumber=0, createdTime=2021-02-28, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f31920e677cb, moduleTitle=礼来制药与信达生物共同宣布达伯舒®（信迪利单抗注射液）非鳞状非小细胞肺癌一线治疗新适应症正式上市, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f31920e677cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416225, encodeId=9b961416225d7, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=新适应症获批！Humira冲击200亿美元有望, objectType=article, longId=207638, objectId=048f20e63867, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=048f20e63867, replyNumber=0, likeNumber=73, createdTime=2021-02-28, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=048f20e63867, moduleTitle=新适应症获批！Humira冲击200亿美元有望, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=048f20e63867)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416224, encodeId=34591416224ab, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=“药王”HUMIRA（阿达木单抗）再获新适应症：FDA批准用于治疗儿童溃疡性结肠炎, objectType=article, longId=207623, objectId=dc2f20e62356, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc2f20e62356, replyNumber=0, likeNumber=70, createdTime=2021-02-27, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc2f20e62356, moduleTitle=“药王”HUMIRA（阿达木单抗）再获新适应症：FDA批准用于治疗儿童溃疡性结肠炎, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=dc2f20e62356)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416223, encodeId=499b1416223ee, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=奥拉帕利新适应症上市申请拟纳入优先审评，治疗前列腺癌, objectType=article, longId=206130, objectId=192220613074, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=192220613074, replyNumber=0, likeNumber=50, createdTime=2021-01-24, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=192220613074, moduleTitle=奥拉帕利新适应症上市申请拟纳入优先审评，治疗前列腺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=192220613074)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416222, encodeId=427a141622230, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=恒瑞医药「甲磺酸阿帕替尼片」新适应症获批：治疗肝细胞癌, objectType=article, longId=205576, objectId=70432055e6e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70432055e6e8, replyNumber=0, likeNumber=76, createdTime=2021-01-11, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70432055e6e8, moduleTitle=恒瑞医药「甲磺酸阿帕替尼片」新适应症获批：治疗肝细胞癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=70432055e6e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416221, encodeId=fe351416221a5, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=GSK贝利尤单抗新适应症获批, objectType=article, longId=204300, objectId=6d47204300dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d47204300dd, replyNumber=0, likeNumber=53, createdTime=2020-12-09, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d47204300dd, moduleTitle=GSK贝利尤单抗新适应症获批, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6d47204300dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416220, encodeId=e65c1416220a7, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=FDA批准RET抑制剂pralsetinib新适应症！治疗甲状腺髓样癌, objectType=article, longId=204111, objectId=394820411175, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=394820411175, replyNumber=0, likeNumber=76, createdTime=2020-12-05, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=394820411175, moduleTitle=FDA批准RET抑制剂pralsetinib新适应症！治疗甲状腺髓样癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=394820411175)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416219, encodeId=820c141621936, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=早期肺癌辅助治疗！奥希替尼新适应症上市申请获FDA优先审评资格, objectType=article, longId=202884, objectId=423720288436, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=423720288436, replyNumber=0, likeNumber=72, createdTime=2020-11-05, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=423720288436, moduleTitle=早期肺癌辅助治疗！奥希替尼新适应症上市申请获FDA优先审评资格, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=423720288436)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416218, encodeId=64a7141621844, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=强生提交Darzalex皮下注射剂新适应症上市申请，治疗轻链淀粉样变性, objectType=article, longId=200589, objectId=14462005895e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14462005895e, replyNumber=0, likeNumber=63, createdTime=2020-09-13, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14462005895e, moduleTitle=强生提交Darzalex皮下注射剂新适应症上市申请，治疗轻链淀粉样变性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=14462005895e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

新适应症

2020-05-29

sunyl08 (审核中...)

前往app查看评论内容

#新适应症#

重磅！欧唐静®（恩格列净片）新适应症在华获批，用于治疗射血分数降低的成人心力衰竭

2022-06-11

sunyl08 (审核中...)

前往app查看评论内容

#新适应症#

“双靶组合”新适应症在我国获批，「达拉非尼」联合「曲美替尼」为BRAF V600突变型非小细胞肺癌患者带来新选择

2022-03-26

sunyl08 (审核中...)

前往app查看评论内容

#新适应症#

再获新适应症！新型三唑类抗真菌药物康新博在我国获批，用于治疗成人侵袭性曲霉病

2022-01-07

sunyl08 (审核中...)

前往app查看评论内容

#新适应症#

今日探报 | 百济神州抗PD-1抗体新适应症有望近期获批；基于NGS的CaptHPV液体活检方法，可用于不同类型HPV肿瘤检测

2022-01-01

sunyl08 (审核中...)

前往app查看评论内容

#新适应症#

君实生物特瑞普利单抗联合化疗一线治疗非小细胞肺癌的新适应症上市申请获受理

2021-12-12

sunyl08 (审核中...)

前往app查看评论内容

#新适应症#

君实生物特瑞普利单抗联合化疗用于鼻咽癌一线治疗的新适应症在中国获批上市

2021-12-02

sunyl08 (审核中...)

前往app查看评论内容

#新适应症#

「依维莫司」新适应症获批，乳腺癌治疗迎来“内分泌+”新时代

2021-11-10

sunyl08 (审核中...)

前往app查看评论内容

#新适应症#

纳入优先审评！恒瑞医药创新药吡咯替尼新适应症——新辅助治疗

2021-09-28

爆笑小医 (审核中...)

前往app查看评论内容

#新适应症#

罗氏重磅新药舒友立乐®在华斩获新适应症，助力更多A型血友病患者迈向“零出血”自由人生

2021-05-02

爆笑小医 (审核中...)

前往app查看评论内容

#新适应症#

葛兰素史克中枢神经系统治疗药物利必通获批双相情感障碍新适应症

2021-03-09

爆笑小医 (审核中...)

前往app查看评论内容

#新适应症#

葛兰素史克中枢神经系统治疗药物利必通获批新适应症，为双相情感障碍患者带来一线用药新选择

2021-03-02

爆笑小医 (审核中...)

前往app查看评论内容

#新适应症#

礼来制药与信达生物共同宣布达伯舒®（信迪利单抗注射液）非鳞状非小细胞肺癌一线治疗新适应症正式上市

2021-02-28

爆笑小医 (审核中...)

前往app查看评论内容

#新适应症#

新适应症获批！Humira冲击200亿美元有望

2021-02-28

爆笑小医 (审核中...)

前往app查看评论内容

#新适应症#

“药王”HUMIRA（阿达木单抗）再获新适应症：FDA批准用于治疗儿童溃疡性结肠炎

2021-02-27

爆笑小医 (审核中...)

前往app查看评论内容

#新适应症#

奥拉帕利新适应症上市申请拟纳入优先审评，治疗前列腺癌

2021-01-24

爆笑小医 (审核中...)

前往app查看评论内容

#新适应症#

恒瑞医药「甲磺酸阿帕替尼片」新适应症获批：治疗肝细胞癌

2021-01-11

爆笑小医 (审核中...)

前往app查看评论内容

#新适应症#

GSK贝利尤单抗新适应症获批

2020-12-09

爆笑小医 (审核中...)

前往app查看评论内容

#新适应症#

FDA批准RET抑制剂pralsetinib新适应症！治疗甲状腺髓样癌

2020-12-05

sunyl08 (审核中...)

前往app查看评论内容

#新适应症#

早期肺癌辅助治疗！奥希替尼新适应症上市申请获FDA优先审评资格

2020-11-05

sunyl08 (审核中...)

前往app查看评论内容

#新适应症#

强生提交Darzalex皮下注射剂新适应症上市申请，治疗轻链淀粉样变性

2020-09-13

科室
- - 订阅+
  - 更多科室
工具
服务